Rockwell Medical (RMTI) furnishes updated corporate presentation in Form 8-K
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Rockwell Medical, Inc. furnished an updated corporate presentation as part of a current report. The presentation, dated March 26, 2026, is attached as Exhibit 99.1 and provides corporate information under Regulation FD.
The company notes this material is furnished, not filed, so it is not subject to certain Exchange Act liabilities and will only be incorporated into other securities filings if specifically referenced.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 7.01, 9.01
2 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 26, 2026
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
(Address of principal executive offices, including zip code)
(248 ) 960-9009
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||||||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||||||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||||||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c) | ||||||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol | Name of Each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.
On March 26, 2026, Rockwell Medical, Inc. made available an updated corporate presentation. A copy of the corporate presentation is furnished herewith as Exhibit 99.1 and incorporated by reference herein.
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits The following exhibit is being furnished herewith:
EXHIBIT INDEX
| Exhibit No. | Description | |||||||
| 99.1 | Rockwell Medical, Inc. Corporate Presentation, dated March 26, 2026 | |||||||
| 104 | Cover Page Interactive Data File, formatted in INline XBRL and included as Exhibit 101. | |||||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ROCKWELL MEDICAL, INC. | ||||||||
| Date: March 26, 2026 | By: | /s/ Mark Strobeck | ||||||
| Mark Strobeck | ||||||||
| Chief Executive Officer | ||||||||
FAQ
What did Rockwell Medical (RMTI) disclose in this Form 8-K?
Rockwell Medical disclosed that it made available an updated corporate presentation. The presentation is dated March 26, 2026 and is attached as Exhibit 99.1, providing investors with additional company information under Regulation FD disclosure rules.
What is Exhibit 99.1 in Rockwell Medical (RMTI)'s filing?
Exhibit 99.1 is Rockwell Medical’s updated corporate presentation dated March 26, 2026. It is furnished with the Form 8-K to share corporate information with the market, but is not treated as filed for certain Securities Exchange Act liability purposes.
Is Rockwell Medical’s (RMTI) corporate presentation considered filed with the SEC?
The corporate presentation is furnished, not filed, with the SEC. Rockwell Medical states that Exhibit 99.1 is not deemed filed under Section 18 of the Securities Exchange Act and will only be incorporated into other filings if specifically referenced.
Which exhibits accompany Rockwell Medical (RMTI)'s March 26, 2026 Form 8-K?
The Form 8-K includes Exhibit 99.1, Rockwell Medical’s corporate presentation dated March 26, 2026, and Exhibit 104, the cover page interactive data file formatted in Inline XBRL and included as Exhibit 101 to the submission.
Why is Rockwell Medical (RMTI)'s Form 8-K labeled as a Regulation FD disclosure?
The Form 8-K is labeled as a Regulation FD disclosure because Rockwell Medical used it to make an updated corporate presentation publicly available. This approach helps ensure fair disclosure of information by furnishing the presentation as Exhibit 99.1 to all investors simultaneously.